AlzeCure Pharma AB (publ) (ALZCUR.ST)
SEK 1.17
(0.0%)
SEK 1.17
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -37.16 Million SEK | 33.67% |
| 2022 | -56.03 Million SEK | 27.96% |
| 2021 | -77.78 Million SEK | -8.99% |
| 2020 | -71.36 Million SEK | -39.92% |
| 2019 | -51 Million SEK | -41.75% |
| 2018 | -35.98 Million SEK | -232.52% |
| 2017 | -10.82 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -8.65 Million SEK | 11.74% |
| 2024 Q1 | -9.8 Million SEK | -0.49% |
| 2023 Q4 | -9.75 Million SEK | -27.45% |
| 2023 FY | -37.16 Million SEK | 33.67% |
| 2023 Q3 | -7.65 Million SEK | 25.03% |
| 2023 Q2 | -10.21 Million SEK | -9.47% |
| 2023 Q1 | -9.32 Million SEK | 14.15% |
| 2022 FY | -56.03 Million SEK | 27.96% |
| 2022 Q3 | -11.02 Million SEK | 48.85% |
| 2022 Q2 | -21.54 Million SEK | -70.39% |
| 2022 Q1 | -12.64 Million SEK | 44.09% |
| 2022 Q4 | -10.86 Million SEK | 1.42% |
| 2021 Q2 | -15.69 Million SEK | 31.66% |
| 2021 FY | -77.78 Million SEK | -8.99% |
| 2021 Q1 | -22.96 Million SEK | -29.58% |
| 2021 Q4 | -22.61 Million SEK | -37.03% |
| 2021 Q3 | -16.5 Million SEK | -5.19% |
| 2020 Q1 | -13.78 Million SEK | 11.84% |
| 2020 Q2 | -18.4 Million SEK | -33.54% |
| 2020 FY | -71.36 Million SEK | -39.92% |
| 2020 Q4 | -17.72 Million SEK | 17.41% |
| 2020 Q3 | -21.45 Million SEK | -16.56% |
| 2019 FY | -51 Million SEK | -41.75% |
| 2019 Q4 | -15.63 Million SEK | -16.84% |
| 2019 Q3 | -13.38 Million SEK | -30.49% |
| 2019 Q2 | -10.25 Million SEK | 11.49% |
| 2019 Q1 | -11.58 Million SEK | 10.65% |
| 2018 Q1 | -9.62 Million SEK | -69.68% |
| 2018 FY | -35.98 Million SEK | -232.52% |
| 2018 Q4 | -12.96 Million SEK | -128.69% |
| 2018 Q3 | -5.67 Million SEK | 26.59% |
| 2018 Q2 | -7.72 Million SEK | 19.74% |
| 2017 Q3 | -5.05 Million SEK | 0.0% |
| 2017 Q4 | -5.67 Million SEK | -12.23% |
| 2017 FY | -10.82 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -171.47% |
| BioGaia AB (publ) | 365.35 Million SEK | 110.173% |
| Enzymatica AB (publ) | -49.72 Million SEK | 25.259% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | 16.69% |
| Gabather AB (publ) | -9.43 Million SEK | -293.843% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | -3.865% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | -76.205% |
| Nanexa AB (publ) | -76.39 Million SEK | 51.351% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | -141.266% |
| ODI Pharma AB | 355.97 Thousand SEK | 10541.019% |
| Orexo AB (publ) | -128.3 Million SEK | 71.031% |
| Probi AB (publ) | 16.81 Million SEK | 320.982% |
| Swedencare AB (publ) | 58.6 Million SEK | 163.425% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 101.543% |
| Toleranzia AB | -7.45 Million SEK | -398.284% |
| Vivesto AB | -367.03 Million SEK | 89.874% |